Dr. Atkinson Discusses the COLUMBUS Trial for Melanoma

Victoria Atkinson, MD
Published: Friday, Oct 20, 2017



Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the COLUMBUS trial for patients with melanoma.

The COLUMBUS trial investigates the combination of encorafenib and binimetinib. Patients who received encorafenib and binimetinib experienced less photosensitivity and rash, which has been seen with the vemurafenib (Zelboraf) and cobimetinib (Cotellic) compounds, states Atkinson.

The COLUMBUS data are unique since it uses the highest dose of a BRAF inhibitor. This is done in the hopes to have the maximum blockade of the MAP-kinase pathway, explains Atkinson. This trial has seen the longest progression-free survival of targeted therapies.

<<< View more from the World Congress of Melanoma


Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the COLUMBUS trial for patients with melanoma.

The COLUMBUS trial investigates the combination of encorafenib and binimetinib. Patients who received encorafenib and binimetinib experienced less photosensitivity and rash, which has been seen with the vemurafenib (Zelboraf) and cobimetinib (Cotellic) compounds, states Atkinson.

The COLUMBUS data are unique since it uses the highest dose of a BRAF inhibitor. This is done in the hopes to have the maximum blockade of the MAP-kinase pathway, explains Atkinson. This trial has seen the longest progression-free survival of targeted therapies.

<<< View more from the World Congress of Melanoma

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x